

1<sup>st</sup> Quarter Ended

September 30, 2022



## **CONTENT**

- 1. Vision and Mission Statement
- 2. Corporate Information
- 3. Director's Report
- 4. Statement of Financial Position
- 5. Statement of Profit and Loss
- 6. Statement of Cash Flows
- 7. Statement of Comprehensive Income
- 8. Statement of Change in Equity
- 9. Notes to the Financial Statements



## **Vision Statement**

To be the unmatched leader in rendering diversified health care services through sustainable process of economy, efficiency and effectiveness.

## **Mission Statement**

To be innovative, effective and efficient in the field of health care to the benefit of society, we will fairly compete in quality, technology, operational expertise, while ensuring sound financial and sustainable growth of the Company for the sake of its stakeholders and reputation.



## **Company Information**

### **Board of Directors**

1. Dr. Zahid Mahmood Chairman

2. Mr. Mansoor Ahmed Soomro Chief Executive Officer

3. Ms. Maaria Ahmad Director4. Mr. Sohail Habib Director

5. Ms. Farzin Khan Independent Director
 6. Mr. Muhammad Iqbal Independent Director
 7. Mr. Usman Ali Shah Independent Director

#### **Audit Committee**

Ms. Farzin Khan
 Mr. Mansoor Ahmed Soomro
 Ms. Maaria Ahmad
 Mr. Adeel Rehman

Chairman

Member

Secretary

### **Human Resource and Remuneration Committee**

Mr. Muhammad Iqbal Chairman
 Mr. Sohail Habib Member
 Ms. Maaria Ahmad Member
 Mr. Muhammad Usman Secretary

**Company Secretary & CFO** Mr. Muhammad Usman

**Head of Internal Auditor** Mr. Adeel Aslam

**Auditors** Kreston Hyder Bhimji & Co. Chartered

Accountants

**Legal Advisor** Azzizuddin & Shahid Law Associates

**Registrar** F.D. Registrar Services (Private) Limited

1705,17<sup>th</sup> Floor, Saima Trade Tower A. I.I

Chundrigar Road Karachi. Phone: +92 (21) 35478192-93 Fax: +92 (21) 32621233

**Registered Office** Office # 508, 5<sup>™</sup> Floor, LSE Building, Aiwan-

e-Igbal, Lahore.



## **Directors' report**

The Directors are pleased to present the un-audited Financial Statements of the Company for the three months' period ending on September 30, 2022.

Certain corporate actions/ decisions have been taken by the Board of Directors in their meeting held on **June 17, 2022** and subsequent approval from the shareholders in their extraordinary general meeting of the Company held on **July 22, 2022**. The key decisions that have been taken by the Board of Directors and the shareholders are as under:

- 1. Approval and implementation of the Revival Business Plan.
- 2. Change of Name of the Company from Hashimi Can Company Limited to the proposed name of **MetaTech Health Limited** to represent its revised/intended business activities.
- 3. Increase in the Company's authorized capital from Rs. 50 million to Rs. 600 million.
- 4. Change in the **Principal Business of the Company under Object Clause** of the Memorandum of Association of the Company to accommodate the intended/planned business activities **for investment in companies focusing on trading/manufacturing/production of advanced/hi-tech healthcare and oral/dental/aesthetic products and services.**
- 5. Relocating the registered office of the Company to the province of Punjab.
- 6. Adopt changes in the Articles of Association of the Company.
- 7. Writing-off/provisioning against past receivables/assets to clean the books of accounts under the "Revival Business Plan" of the Company.

To implement the "Revival Business Plan", the Board of Directors have decided to raise requisite funds through MetaTech Health Limited – **Perpetual and Convertible Sukuk** ("the Sukuk") that is being offered to the existing shareholders by way of Right under relevant rules and regulations.

The quantum of the Right Issue is approximately 550% of the existing paid up capital of the Company i.e. approximately 550 right Sukuk for every 100 ordinary shares held by the shareholders of the Company i.e. The Company shall issue 40,878,338 Sukuk, at a price of PKRs. 10/- per Sukuk, aggregating to PKRs. 408,783,380/-

The Company is in the process to develop and operate **Ensmile Studios** across the Country and also intends to make equity investment in Ensmile (Private) Limited up to Rs. 300.00 million (as per "Revival Business Plan").

### **Web Presence**

Company's periodic financial statements for the current financial year including annual reports for the last three years are available on the Company's website for information of the investors.

On behalf of Board of Directors of the company, I am thankful to all worthy shareholders and staff members of the company for their untiring efforts for the betterment of the company.



### **Acknowledgements**

We wish to place on record gratitude to our valued customers for their confidence in our products and we pledge ourselves to provide them the best quality by continuously improving our products. We would also like to thank all our colleagues, management and staffs who are strongly committed to their work as the success of your Company is built around their efforts. We also thank our shareholders for their confidence in the Company and assure them that we are committed to do our best to ensure best rewards for their investment in the Company.

For and on Behalf of the Board

**Chief Executive Officer** 

Dated: October 31, 2022

Place: Lahore



## **FINANCIALS**

# CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION (UN-AUDITED) AS AT SEPTEMBER 30, 2022

AS AT SEPTEM	DER 30,	2022	
		Un-Audited 30-Sep-22	Audited 30-Jun-22
	Note	Rupees	Rupees
CURRENT ASSETS			
Trade debts	5	2,554,975	-
Advances to Suppliers		502,226	-
Short term investments	6	100,000,000	-
Prepayments, Advances and Others	7	49,553,755	34,346,314
Refund due from Govt net		197,732	145,569
Cash and bank balances	8	27,515,546	144,604,465
		180,324,234	179,096,348
		180,324,234	179,096,348
EQUITY AND LIABILITIES SHARE CAPITAL AND RESERVES			
Authorized capital			
5,000,000 (2022: 5,000,000) Ordinary sha Rs. 10/- each	res of	50,000,000	50,000,000
·			
Issued, subscribed and paid-up-capital	9	74,324,250	16,335,000
Unappropriated profit		62,250	57,546,308
		74,386,500	73,881,308
CURRENT LIABILITIES			
	10	2.520.027	22.710.167
Accrued & Other Payable	10	2,520,824	22,719,164
Short term loan - Unsecured	]]	3,416,910	82,495,877
Payable to DCCL	12	100,000,000	105 215 071
Contingencies and commitments		105,937,734	105,215,041
Contingencies and commitments		-	-
		180,324,234	179,096,348
27			

CHIEF EXECUTIVE



# CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED) FOR THE PERIOD ENDED SEPTEMBER 30, 2022

	Note	Un-Audited 30-Sep-22 Rupees	Un-Audited 30-Sep-21 Rupees
Sales Less: Cost of sales Gross profit / (loss)		4,277,975 (1,648,000) 2,629,975	
Administrative and selling expenses	13	3,552,290	903,265
Operating (loss)		3,552,290 (922,315)	(903,265)
Other income		1,491,677	-
Financial charges Net profit / ( loss) before taxation		 569,362	(903,265)
Taxation		(64,170)	-
Net profit / (loss) after taxation		505,192	(903,265)
Earning / (Loss) per share - Basic		0.07	(0.55)

CHIEF EXECUTIVE



# CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED SEPTEMBER 30, 2022

	<b>Un-Audited</b>	Un- Audited	
	30 Sep 2022	30 Sep 2022	
	Rupees	Rupees	
Net profit / (loss) after taxation	505,192	(903,265)	
Other comprehensive income			
Other comprehensive income / (loss) which will not be reclassified to profit or loss in subsequent periods	-	-	
Total comprehensive profit / (loss) for the period	505,192	(903,265)	

The annexed notes form an integral part of these financial statements.

CHIEF EXECUTIVE



# CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED SEPTEMBER 30, 2022

Share

**Capital** 

Issued,

Revenue

reserves

	subscribe d and paid- up capital	Unappropri ated profit	Total ees
	•		
Balance as at July 01, 2021	16,335,000	57,204,327	73,539,327
Loss for the year	-	341,981	341,981
Other comprehensive income	-	-	-
Balance as at June 30, 2022 - Audited	16,335,000	57,546,308	73,881,308
Balance as at July 01, 2022	16,335,000	57,546,308	73,881,308
Bonus Shares 5,798,925 Issued @ 3.55 per shareholder	57,989,250	(57,989,250)	-
Profit for the year	-	505,192	505,192
Other comprehensive income	-	-	-
Balance as at September 30, 2022 -Un-Audited	74,324,250	62,250	74,386,500



## CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED) FOR THE PERIOD ENDED SEPTEMBER 30, 2022

	Un-Audited 30 Sep 2022 Rupees	Un-Audited 30 Sep 2021 Rupees
CASH FROM OPERATION ACTIVTIES	•	•
Net Profit (loss) before taxation <b>Adjustments for:</b>	505,192	903,265)
Depreciation		385 385
Operating (loss) before working capital changes	505,192	(902,880)
(Increase) / decrease in current assets	(7.050.00)	
Advance deposit and prepayments Prepayments, Advances and Others Increase / (decrease) in current liabilities	(3,057,201) (15,207,441)	-
Accrued & Other Payable	(99,277,307)	_
•	(117,541,949)	-
Income tax paid	(52,161)	
Net cash generate / (used in) operating activities	(117,088,918)	(902,880)
CASH FROM INVESTING ACTIVITIES		
Short term investment	(100,000,000)	-
Net cash generated / (used in) from investing activities	(100,000,000)	-
CASH FROM FINANCING ACTIVITES		
Net cash generated from financing activities	100,000,000	-
Net increase / (decrease) cash and cash equivalents	(117,088,919)	(902,881)
Cash and cash equivalents at the beginning of the period	144,604,465	145,507,346
Cash and cash equivalents at the end of the period	27,515,546	144,604,465

The annexed notes form an integral part of these financial statements.

CHIEF EXECUTIVE



### NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED SEPTEMBER 30, 2022

### 1 NATURE AND STATUS OF BUSINESS

The Company was incorporated in Pakistan in 1953 as a public Limited Company and its shares were listed on the Karachi (now Pakistan) Stock Exchange. Due to closure of its plant and disposal of manufacturing facilities, the Company had long become a dormant Company. However, during the year, the Board of Directors, while approving the revival business plan, had decided to change the principal business of the Company to operate in the technology-enabled healthcare business & services. The Company's registered office is Office No. 01, Ground Floor, Building No. 31C, Noor Heights, Jami Commercial Street 02, Phase VII, DHA, Karachi.

1.1 Post of the year end and upon the unanimous approval of the revival business plan by the Shareholders, the Company has resumed its commercial / business activities/operations in the new / revised line of business. Furthermore, the Company's name has also been changed to M/s MetaTech Health Limited after approval from the Securities & Exchange Commission of Pakistan as on August 02, 2022.

### 1.2 GOING CONCERN ASSUMPTION

Subsequent to the accounting period under review, the Company, under the management of Modaraba Al Mali (a PSX listed Islamic Fund focusing on the corporate restructurings and revival activities) has signed a Term Sheet with M/s Ensmile for an investment of PKR 300Mn (including an advance of PKR 100Mn to be completed by December 31, 2022), and has also taken-over the Operations and Management of Ensmile's Digital Dental Aligners Studios in Pakistan. Besides this, the Company has also appointed the Underwriters and Consultant to the Issue Advisors for raising about PKR 408Mn from the market sources through the right shares issuance. The Company has also started booking revenue from the Islamabad based Dental Aligners Studio of Ensmile.

All of the above actions tantamount to our considered opinion that the Company is fully on-track to complete its turn-around and become a going concern (the same has also been affirmed in the auditors' certificate issued subsequent to the reporting date) as compared to the previous adverse opinion about doubtful going-concern prospects of the Company's financial position existing on Jun 30, 2021. Furthermore, the involvement of Modaraba Al Mali in the revival of the Company provides a stronger probability for the Company to continue as a going concern and discharge its liabilities in the normal course of business. Accordingly, the going concern assumption used by the Company for the preparation of these Financial Statements seems valid and appropriate.

### 2 BASIS OF PREPARATION

This condensed interim financial information has been prepared in accordance with approved accounting standards as applicable in Pakistan.



Approved accounting standards comprise of such International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board as are notified under the Companies Ordinance, 1984 provisions of and directives issued under the Companies Act, 2017. Wherever the requirements of the Companies Act, 2017, differ with the requirements of IFRS, the requirements of the Companies Act, 2017 shall prevail.

This condensed interim financial information does not include all information required for annual financial statements and therefore should be read in conjunction with the annual financial statements for the year ended June 30, 2022.

The management of the Company is confident that it will be able to meet its obligations and carry on business without any curtailment based on the grounds that the Company will be able to achieve satisfactory level of profitability in the future based on the plans drawn up by the management for this purpose, which include income arising from rentals and investments.

### **3 ACCOUNTING POLICIES**

The significant accounting policies are adopted in the preparation of these financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

#### **4 TAXATION**

Income tax expense is recognized based on management's best estimate of the weighted average annual income tax rate expected for the full financial year.



### NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED SEPTEMBER 30, 2022

		Un-Audited 30 Sep 2022 Rupees	Audited 30-Jun-22 Rupees
5	TRADE DEBTORS		
	Considered good		
	Considered doubtful	2,554,975	2,129,640
	considered dediction		3,315,048
	Less: Provision for expected credit losses	2,554,975 -	5,444,688
	(Note 5.1)		(5,444,688)
		2,554,975	
5.1	The amount is receivable form Ensmile (Pvt	) Limited.	
6	LOAN TO ENSMILE (PVT) LIMITED 6.1	100,000,000	

6.1 Rs. 100 million has been paid to Ensmile (Pvt) Limited for equity investment. The issuance of shares is in process

## 7 ADVANCES, DEPOSITS AND PREPAYMENTS

## Advances - unsecured, considered good

good		
- Prepayments	34,346,314	34,346,314
- Advance to suppliers  Less: Provision for expected credit losses	22,445,196	7,237,755
	(7,237,755)	(7,237,755)
	49,553,755	34,346,314
	49,553,755	34,346,314



### NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED SEPTEMBER 30, 2022

		Un-Audited 30 Sep 2022 Rupees	Audited 30 June 2022 Rupees
8	CASH AND BANK BALANCES		
	Cash in hand Pay order in hand Cash at bank - current account	27,515,546 27,515,546	101,917 23,217,355 121,285,193
9	SHARE CAPITAL		
	Authorised capital		
	5,000,000 (2021: 5,000,000) Ordinary shares of Rs. 10/- each	50,000,000	50,000,000
	Issued, subscribed and paid up capital		
	1,034,500 (2021: 1,034,500) Ordinary shares of	10,345,000	10,345,000
	Rs. 10/- each fully paid up in cash		
	170,000 (2021: 170,000) Ordinary shares of Rs.10/- each fully paid, issued for consideration other than cash	1,700,000	1,700,000
	429,000 (2021: 429,000) Ordinary shares of Rs. 10/- each issued as fully paid up bonus shares	4,290,000	4,290,000
	5,798,925 (2022: NIL) Ordinary shares of Rs. 10/- each issued as fully paid up bonus shares	57,989,250	-
		74,324,250	16,335,000
10	CREDITORS, PROVISIONS AND ACCRUED C	HARGES	
	Accrued expenses	2,520,823	225,000
	Liabilities against Settlements & Contingencies		22,494,164
		2,520,823	22,719,164

### 11 SHORT TERM LOAN - UNSECURED



	Directors Loan		-	-
	Modaraba Al Mali - MODAM	11.1	3,416,910	82,495,877
			3,416,910	82,495,877
11.1	This loan is repayable by the (Modaraba Al-Mali) now.	e Company	on demand to	the assignee
12	PAYABLE TO DCCL			
	Loan from DCCL	12.1	100,000,000	
			100,000,000	
12.1 13	The Company has obtained a los Company Limited (DCCL) on a te ADMINISTRATIVE AND SELLING EXPENSES	erm of Avg. 3		
	Rent, Rates and Taxes		1,066,000	-
	Salaries & Wages		1,564,864	-
	Legal and professional charges		-	903,265
	Travelling & Conveyance		181,080	-
	Utilities		13,502	-
	Printing & Stationery		20,000	-
	Advertisement and Marketing		706,844	
	5		3,552,290	903,265
14	DATE OF AUTHORIZATION			

These financial statements have been authorized for issue on \_ by the Board of Directors of the Company.

CHIEF EXECUTIVE



If Undelivered Please Return to:

## **METATECH HEALTH LIMITED**

(FORMERLY HASHIMI CAN COMPANY LIMITED)

Office No. 508, 5<sup>th</sup> Floor, LSE Building, Aiwan-e-Iqbal, Lahore, Pakistan

Phone: +92 42 3636000 Fax: +92 42 3636001

